| 1 | crossover | 7,573 |
| 2 | cross-over | 2,794 |
| 3 | factorial | 1,401 |
| 4 | split-mouth | 327 |
| 5 | dose-escalation | 246 |
| 6 | dose-ranging | 236 |
| 7 | dose-finding | 205 |
| 8 | between-subjects | 162 |
| 9 | pretest-posttest | 136 |
| 10 | within-subjects | 135 |
| 11 | dose-escalating | 62 |
| 12 | parallel-groups | 40 |
| 13 | quasiexperimental | 32 |
| 14 | box-behnken | 31 |
| 15 | ascending-dose | 28 |
| 16 | split-plot | 22 |
| 17 | full-factorial | 20 |
| 18 | four-group | 19 |
| 19 | plackett-burman | 19 |
| 20 | posttest-only | 18 |
| 21 | latin-square | 17 |
| 22 | paired-eye | 17 |
| 23 | between-participants | 16 |
| 24 | forced-titration | 16 |
| 25 | multiple-baseline | 16 |
| 26 | pretest/posttest | 15 |
| 27 | d-optimal | 14 |
| 28 | play-the-winner | 14 |
| 29 | pre-test-post-test | 13 |
| 30 | crxo | 12 |
| 31 | fixed-sequence | 12 |
| 32 | pretest-post-test | 12 |
| 33 | crossover-design | 11 |
| 34 | factorial-design | 11 |
| 35 | pre-/post-test | 11 |
| 36 | randomized-control | 11 |
| 37 | switchback | 11 |
| 38 | multiarm | 10 |
| 39 | triple-crossover | 10 |
| 40 | 2-factorial | 9 |
| 41 | 4-group | 9 |
| 42 | 4-phase | 9 |
| 43 | d-efficient | 9 |
| 44 | double-crossover | 8 |
| 45 | dietary-intervention | 7 |
| 46 | within-participants | 7 |
| 47 | crossover-designed | 6 |
| 48 | dog-leg | 6 |
| 49 | randomized-crossover | 6 |
| 50 | rising-dose | 6 |
| 51 | split-scar | 6 |
| 52 | alsympca | 5 |
| 53 | change-over | 5 |
| 54 | pre-/posttest | 5 |
| 55 | three-outcome | 5 |
| 56 | user-centred | 5 |
| 57 | δ-minimax | 5 |
| 58 | 2-cohort | 4 |
| 59 | conversion-to-monotherapy | 4 |
| 60 | exophthalmometer | 4 |
| 61 | half-mouth | 4 |
| 62 | multiple-crossover | 4 |
| 63 | placebo-phase | 4 |
| 64 | sequential-group | 4 |
| 65 | two-parallel-group | 4 |
| 66 | 6-visit | 3 |
| 67 | case-vignette | 3 |
| 68 | complete-block | 3 |
| 69 | controlled-clinical | 3 |
| 70 | double-armed | 3 |
| 71 | double-blind-randomized | 3 |
| 72 | pre-post-test | 3 |
| 73 | scami | 3 |
| 74 | self-crossover | 3 |
| 75 | simulated-use | 3 |
| 76 | treatment-assignment | 3 |
| 77 | trias | 3 |
| 78 | two-eye | 3 |
| 79 | within-between | 3 |
| 80 | -assigned | 2 |
| 81 | 20-d | 2 |
| 82 | 27-d | 2 |
| 83 | a5230 | 2 |
| 84 | biomarker-stratified | 2 |
| 85 | block-designed | 2 |
| 86 | buma-oct | 2 |
| 87 | costami | 2 |
| 88 | cross-over-like | 2 |
| 89 | dose-confirmation | 2 |
| 90 | enid | 2 |
| 91 | fixeddose | 2 |
| 92 | flot65+ | 2 |
| 93 | four-sequence | 2 |
| 94 | household-randomized | 2 |
| 95 | intervention.this | 2 |
| 96 | lym3001 | 2 |
| 97 | measure.the | 2 |
| 98 | one-eye | 2 |
| 99 | parallelgroup | 2 |
| 100 | part-blinded | 2 |
| 101 | penthifra-plus | 2 |
| 102 | pretest/posttest/follow-up | 2 |
| 103 | prospective-cohort | 2 |
| 104 | pulse-sequence | 2 |
| 105 | regimen-finding | 2 |
| 106 | regression-discontinuity | 2 |
| 107 | scaffold-like | 2 |
| 108 | semi-crossover | 2 |
| 109 | single-orifice | 2 |
| 110 | single-participant | 2 |
| 111 | single-reversal | 2 |
| 112 | splitmouth | 2 |
| 113 | step-wedged | 2 |
| 114 | test-of-concept | 2 |
| 115 | titration-to-effect | 2 |
| 116 | torava | 2 |
| 117 | two-attack | 2 |
| 118 | two-crossover | 2 |
| 119 | vaccine-probe | 2 |
| 120 | within/between-subjects | 2 |
| 121 | 'superiority | 1 |
| 122 | 1,160-patient | 1 |
| 123 | 108-day | 1 |
| 124 | 130,466 | 1 |
| 125 | 19,897 | 1 |
| 126 | 2,2,2-cross-over | 1 |
| 127 | 234-patient | 1 |
| 128 | 3-station | 1 |
| 129 | 4-condition | 1 |
| 130 | 448,928 | 1 |
| 131 | 72-wk | 1 |
| 132 | 9-factor | 1 |
| 133 | acetaminophen-controlled | 1 |
| 134 | analysis.acupuncture | 1 |
| 135 | antacid-controlled | 1 |
| 136 | balanced-block | 1 |
| 137 | barite-type | 1 |
| 138 | battenburg | 1 |
| 139 | between-measures | 1 |
| 140 | between-persons | 1 |
| 141 | between/within-subjects | 1 |
| 142 | box-wilson | 1 |
| 143 | cardio133 | 1 |
| 144 | case-pseudocontrol | 1 |
| 145 | change-to-open-label | 1 |
| 146 | cluster-crossover | 1 |
| 147 | co-relational | 1 |
| 148 | cohort-sequential | 1 |
| 149 | control-comparative | 1 |
| 150 | cpgs-based | 1 |
| 151 | cross-sectional/stratified | 1 |
| 152 | cross-sequential | 1 |
| 153 | crossover-combination | 1 |
| 154 | danish-dutch | 1 |
| 155 | delayed-control | 1 |
| 156 | delivery.study | 1 |
| 157 | diabetes.the | 1 |
| 158 | diamondoid | 1 |
| 159 | dimethyldihydropyrene | 1 |
| 160 | dose-validation | 1 |
| 161 | double/triple-blinded | 1 |
| 162 | doxycycline-metronidazole | 1 |
| 163 | effectiveness/implementation | 1 |
| 164 | eortc-22972/mrc-br10 | 1 |
| 165 | equivalent-control | 1 |
| 166 | escalation/descalation | 1 |
| 167 | eurofors | 1 |
| 168 | event-related/block | 1 |
| 169 | factorial-rct | 1 |
| 170 | fix-hf-5 | 1 |
| 171 | fluoxetine-discontinuation | 1 |
| 172 | food-challenge-proven | 1 |
| 173 | forced-switching | 1 |
| 174 | formula-controlled | 1 |
| 175 | h.mean | 1 |
| 176 | healthservices | 1 |
| 177 | hearthealthy | 1 |
| 178 | immunotherapy.this | 1 |
| 179 | impact-1 | 1 |
| 180 | independent-groups | 1 |
| 181 | intervention-study | 1 |
| 182 | intervention/usual-care | 1 |
| 183 | investigator-open | 1 |
| 184 | isthe | 1 |
| 185 | itb01 | 1 |
| 186 | longitudinal-observational | 1 |
| 187 | method/study | 1 |
| 188 | methods/trial | 1 |
| 189 | mock-package | 1 |
| 190 | mock-packaged | 1 |
| 191 | ms231 | 1 |
| 192 | multioccasion | 1 |
| 193 | multiple-probe | 1 |
| 194 | n-g-dimethylarginine | 1 |
| 195 | no-inferiority | 1 |
| 196 | nonequivalent-groups | 1 |
| 197 | one-group-only | 1 |
| 198 | one-group-repeated-measures | 1 |
| 199 | one-nostril | 1 |
| 200 | oulu-bpd | 1 |
| 201 | outcomes-measure | 1 |
| 202 | paired-study | 1 |
| 203 | paraffin-adsorption | 1 |
| 204 | parallel-study | 1 |
| 205 | partially-nested | 1 |
| 206 | pascart | 1 |
| 207 | pbr-relevant | 1 |
| 208 | pens/feeder | 1 |
| 209 | penta-gonal | 1 |
| 210 | pilot-randomized | 1 |
| 211 | placebo-challenging | 1 |
| 212 | pre-/post- | 1 |
| 213 | pre-and-post-intervention | 1 |
| 214 | pre-post-control | 1 |
| 215 | pre-post-randomized | 1 |
| 216 | pre-post-treatment | 1 |
| 217 | pre-test-posttest | 1 |
| 218 | pre-test/posttest/follow-up | 1 |
| 219 | pre-test–post-test | 1 |
| 220 | pre/post-test | 1 |
| 221 | prefactorial-postfactorial | 1 |
| 222 | pretest-test-posttest | 1 |
| 223 | pretest-training-posttest | 1 |
| 224 | pretestposttest | 1 |
| 225 | prevention+treatment | 1 |
| 226 | protocols.the | 1 |
| 227 | psychophenomenological | 1 |
| 228 | pv16000 | 1 |
| 229 | randomised-counterbalanced | 1 |
| 230 | randomised-crossover | 1 |
| 231 | randomized-block | 1 |
| 232 | randomized-cluster | 1 |
| 233 | randomized-to-order | 1 |
| 234 | rated-blind | 1 |
| 235 | rcts.twelve | 1 |
| 236 | reactt | 1 |
| 237 | reinforcer-controlled | 1 |
| 238 | remote-confederate | 1 |
| 239 | responsive-adaptive | 1 |
| 240 | risperidone-compared | 1 |
| 241 | rt/ct | 1 |
| 242 | semicrossover | 1 |
| 243 | sequential-factorial | 1 |
| 244 | single-subjects | 1 |
| 245 | singleblinded | 1 |
| 246 | split-current-lead | 1 |
| 247 | stiffness-adjustable | 1 |
| 248 | stroke.one | 1 |
| 249 | supersecondary | 1 |
| 250 | test-vein | 1 |
| 251 | test/re-test | 1 |
| 252 | three-formulation | 1 |
| 253 | three-parallel-groups | 1 |
| 254 | topiq-ii | 1 |
| 255 | treatment-comparison | 1 |
| 256 | two-period-crossover | 1 |
| 257 | uht-htst | 1 |
| 258 | un-blind | 1 |
| 259 | user-motivated | 1 |
| 260 | variable-block | 1 |
| 261 | wait-list-controlled | 1 |
| 262 | web-user | 1 |
| 263 | within-wound | 1 |
| 264 | wm1 | 1 |
| 265 | years.study | 1 |
| 266 | zelen-like | 1 |
| 1 | 'superiority | 1 |
| 2 | -assigned | 2 |
| 3 | 1,160-patient | 1 |
| 4 | 108-day | 1 |
| 5 | 130,466 | 1 |
| 6 | 19,897 | 1 |
| 7 | 2,2,2-cross-over | 1 |
| 8 | 2-cohort | 4 |
| 9 | 2-factorial | 9 |
| 10 | 20-d | 2 |
| 11 | 234-patient | 1 |
| 12 | 27-d | 2 |
| 13 | 3-station | 1 |
| 14 | 4-condition | 1 |
| 15 | 4-group | 9 |
| 16 | 4-phase | 9 |
| 17 | 448,928 | 1 |
| 18 | 6-visit | 3 |
| 19 | 72-wk | 1 |
| 20 | 9-factor | 1 |
| 21 | a5230 | 2 |
| 22 | acetaminophen-controlled | 1 |
| 23 | alsympca | 5 |
| 24 | analysis.acupuncture | 1 |
| 25 | antacid-controlled | 1 |
| 26 | ascending-dose | 28 |
| 27 | balanced-block | 1 |
| 28 | barite-type | 1 |
| 29 | battenburg | 1 |
| 30 | between-measures | 1 |
| 31 | between-participants | 16 |
| 32 | between-persons | 1 |
| 33 | between-subjects | 162 |
| 34 | between/within-subjects | 1 |
| 35 | biomarker-stratified | 2 |
| 36 | block-designed | 2 |
| 37 | box-behnken | 31 |
| 38 | box-wilson | 1 |
| 39 | buma-oct | 2 |
| 40 | cardio133 | 1 |
| 41 | case-pseudocontrol | 1 |
| 42 | case-vignette | 3 |
| 43 | change-over | 5 |
| 44 | change-to-open-label | 1 |
| 45 | cluster-crossover | 1 |
| 46 | co-relational | 1 |
| 47 | cohort-sequential | 1 |
| 48 | complete-block | 3 |
| 49 | control-comparative | 1 |
| 50 | controlled-clinical | 3 |
| 51 | conversion-to-monotherapy | 4 |
| 52 | costami | 2 |
| 53 | cpgs-based | 1 |
| 54 | cross-over | 2,794 |
| 55 | cross-over-like | 2 |
| 56 | cross-sectional/stratified | 1 |
| 57 | cross-sequential | 1 |
| 58 | crossover | 7,573 |
| 59 | crossover-combination | 1 |
| 60 | crossover-design | 11 |
| 61 | crossover-designed | 6 |
| 62 | crxo | 12 |
| 63 | d-efficient | 9 |
| 64 | d-optimal | 14 |
| 65 | danish-dutch | 1 |
| 66 | delayed-control | 1 |
| 67 | delivery.study | 1 |
| 68 | diabetes.the | 1 |
| 69 | diamondoid | 1 |
| 70 | dietary-intervention | 7 |
| 71 | dimethyldihydropyrene | 1 |
| 72 | dog-leg | 6 |
| 73 | dose-confirmation | 2 |
| 74 | dose-escalating | 62 |
| 75 | dose-escalation | 246 |
| 76 | dose-finding | 205 |
| 77 | dose-ranging | 236 |
| 78 | dose-validation | 1 |
| 79 | double-armed | 3 |
| 80 | double-blind-randomized | 3 |
| 81 | double-crossover | 8 |
| 82 | double/triple-blinded | 1 |
| 83 | doxycycline-metronidazole | 1 |
| 84 | effectiveness/implementation | 1 |
| 85 | enid | 2 |
| 86 | eortc-22972/mrc-br10 | 1 |
| 87 | equivalent-control | 1 |
| 88 | escalation/descalation | 1 |
| 89 | eurofors | 1 |
| 90 | event-related/block | 1 |
| 91 | exophthalmometer | 4 |
| 92 | factorial | 1,401 |
| 93 | factorial-design | 11 |
| 94 | factorial-rct | 1 |
| 95 | fix-hf-5 | 1 |
| 96 | fixed-sequence | 12 |
| 97 | fixeddose | 2 |
| 98 | flot65+ | 2 |
| 99 | fluoxetine-discontinuation | 1 |
| 100 | food-challenge-proven | 1 |
| 101 | forced-switching | 1 |
| 102 | forced-titration | 16 |
| 103 | formula-controlled | 1 |
| 104 | four-group | 19 |
| 105 | four-sequence | 2 |
| 106 | full-factorial | 20 |
| 107 | h.mean | 1 |
| 108 | half-mouth | 4 |
| 109 | healthservices | 1 |
| 110 | hearthealthy | 1 |
| 111 | household-randomized | 2 |
| 112 | immunotherapy.this | 1 |
| 113 | impact-1 | 1 |
| 114 | independent-groups | 1 |
| 115 | intervention-study | 1 |
| 116 | intervention.this | 2 |
| 117 | intervention/usual-care | 1 |
| 118 | investigator-open | 1 |
| 119 | isthe | 1 |
| 120 | itb01 | 1 |
| 121 | latin-square | 17 |
| 122 | longitudinal-observational | 1 |
| 123 | lym3001 | 2 |
| 124 | measure.the | 2 |
| 125 | method/study | 1 |
| 126 | methods/trial | 1 |
| 127 | mock-package | 1 |
| 128 | mock-packaged | 1 |
| 129 | ms231 | 1 |
| 130 | multiarm | 10 |
| 131 | multioccasion | 1 |
| 132 | multiple-baseline | 16 |
| 133 | multiple-crossover | 4 |
| 134 | multiple-probe | 1 |
| 135 | n-g-dimethylarginine | 1 |
| 136 | no-inferiority | 1 |
| 137 | nonequivalent-groups | 1 |
| 138 | one-eye | 2 |
| 139 | one-group-only | 1 |
| 140 | one-group-repeated-measures | 1 |
| 141 | one-nostril | 1 |
| 142 | oulu-bpd | 1 |
| 143 | outcomes-measure | 1 |
| 144 | paired-eye | 17 |
| 145 | paired-study | 1 |
| 146 | paraffin-adsorption | 1 |
| 147 | parallel-groups | 40 |
| 148 | parallel-study | 1 |
| 149 | parallelgroup | 2 |
| 150 | part-blinded | 2 |
| 151 | partially-nested | 1 |
| 152 | pascart | 1 |
| 153 | pbr-relevant | 1 |
| 154 | pens/feeder | 1 |
| 155 | penta-gonal | 1 |
| 156 | penthifra-plus | 2 |
| 157 | pilot-randomized | 1 |
| 158 | placebo-challenging | 1 |
| 159 | placebo-phase | 4 |
| 160 | plackett-burman | 19 |
| 161 | play-the-winner | 14 |
| 162 | posttest-only | 18 |
| 163 | pre-/post- | 1 |
| 164 | pre-/post-test | 11 |
| 165 | pre-/posttest | 5 |
| 166 | pre-and-post-intervention | 1 |
| 167 | pre-post-control | 1 |
| 168 | pre-post-randomized | 1 |
| 169 | pre-post-test | 3 |
| 170 | pre-post-treatment | 1 |
| 171 | pre-test-post-test | 13 |
| 172 | pre-test-posttest | 1 |
| 173 | pre-test/posttest/follow-up | 1 |
| 174 | pre-test–post-test | 1 |
| 175 | pre/post-test | 1 |
| 176 | prefactorial-postfactorial | 1 |
| 177 | pretest-post-test | 12 |
| 178 | pretest-posttest | 136 |
| 179 | pretest-test-posttest | 1 |
| 180 | pretest-training-posttest | 1 |
| 181 | pretest/posttest | 15 |
| 182 | pretest/posttest/follow-up | 2 |
| 183 | pretestposttest | 1 |
| 184 | prevention+treatment | 1 |
| 185 | prospective-cohort | 2 |
| 186 | protocols.the | 1 |
| 187 | psychophenomenological | 1 |
| 188 | pulse-sequence | 2 |
| 189 | pv16000 | 1 |
| 190 | quasiexperimental | 32 |
| 191 | randomised-counterbalanced | 1 |
| 192 | randomised-crossover | 1 |
| 193 | randomized-block | 1 |
| 194 | randomized-cluster | 1 |
| 195 | randomized-control | 11 |
| 196 | randomized-crossover | 6 |
| 197 | randomized-to-order | 1 |
| 198 | rated-blind | 1 |
| 199 | rcts.twelve | 1 |
| 200 | reactt | 1 |
| 201 | regimen-finding | 2 |
| 202 | regression-discontinuity | 2 |
| 203 | reinforcer-controlled | 1 |
| 204 | remote-confederate | 1 |
| 205 | responsive-adaptive | 1 |
| 206 | rising-dose | 6 |
| 207 | risperidone-compared | 1 |
| 208 | rt/ct | 1 |
| 209 | scaffold-like | 2 |
| 210 | scami | 3 |
| 211 | self-crossover | 3 |
| 212 | semi-crossover | 2 |
| 213 | semicrossover | 1 |
| 214 | sequential-factorial | 1 |
| 215 | sequential-group | 4 |
| 216 | simulated-use | 3 |
| 217 | single-orifice | 2 |
| 218 | single-participant | 2 |
| 219 | single-reversal | 2 |
| 220 | single-subjects | 1 |
| 221 | singleblinded | 1 |
| 222 | split-current-lead | 1 |
| 223 | split-mouth | 327 |
| 224 | split-plot | 22 |
| 225 | split-scar | 6 |
| 226 | splitmouth | 2 |
| 227 | step-wedged | 2 |
| 228 | stiffness-adjustable | 1 |
| 229 | stroke.one | 1 |
| 230 | supersecondary | 1 |
| 231 | switchback | 11 |
| 232 | test-of-concept | 2 |
| 233 | test-vein | 1 |
| 234 | test/re-test | 1 |
| 235 | three-formulation | 1 |
| 236 | three-outcome | 5 |
| 237 | three-parallel-groups | 1 |
| 238 | titration-to-effect | 2 |
| 239 | topiq-ii | 1 |
| 240 | torava | 2 |
| 241 | treatment-assignment | 3 |
| 242 | treatment-comparison | 1 |
| 243 | trias | 3 |
| 244 | triple-crossover | 10 |
| 245 | two-attack | 2 |
| 246 | two-crossover | 2 |
| 247 | two-eye | 3 |
| 248 | two-parallel-group | 4 |
| 249 | two-period-crossover | 1 |
| 250 | uht-htst | 1 |
| 251 | un-blind | 1 |
| 252 | user-centred | 5 |
| 253 | user-motivated | 1 |
| 254 | vaccine-probe | 2 |
| 255 | variable-block | 1 |
| 256 | wait-list-controlled | 1 |
| 257 | web-user | 1 |
| 258 | within-between | 3 |
| 259 | within-participants | 7 |
| 260 | within-subjects | 135 |
| 261 | within-wound | 1 |
| 262 | within/between-subjects | 2 |
| 263 | wm1 | 1 |
| 264 | years.study | 1 |
| 265 | zelen-like | 1 |
| 266 | δ-minimax | 5 |
| 1 | flot65+ | 2 |
| 2 | pre-/post- | 1 |
| 3 | pv16000 | 1 |
| 4 | eortc-22972/mrc-br10 | 1 |
| 5 | a5230 | 2 |
| 6 | impact-1 | 1 |
| 7 | lym3001 | 2 |
| 8 | itb01 | 1 |
| 9 | ms231 | 1 |
| 10 | wm1 | 1 |
| 11 | cardio133 | 1 |
| 12 | fix-hf-5 | 1 |
| 13 | 130,466 | 1 |
| 14 | 19,897 | 1 |
| 15 | 448,928 | 1 |
| 16 | alsympca | 5 |
| 17 | torava | 2 |
| 18 | 20-d | 2 |
| 19 | 27-d | 2 |
| 20 | split-current-lead | 1 |
| 21 | randomised-counterbalanced | 1 |
| 22 | double/triple-blinded | 1 |
| 23 | part-blinded | 2 |
| 24 | singleblinded | 1 |
| 25 | mock-packaged | 1 |
| 26 | step-wedged | 2 |
| 27 | biomarker-stratified | 2 |
| 28 | cross-sectional/stratified | 1 |
| 29 | formula-controlled | 1 |
| 30 | antacid-controlled | 1 |
| 31 | acetaminophen-controlled | 1 |
| 32 | reinforcer-controlled | 1 |
| 33 | wait-list-controlled | 1 |
| 34 | double-armed | 3 |
| 35 | block-designed | 2 |
| 36 | crossover-designed | 6 |
| 37 | -assigned | 2 |
| 38 | risperidone-compared | 1 |
| 39 | user-centred | 5 |
| 40 | cpgs-based | 1 |
| 41 | user-motivated | 1 |
| 42 | partially-nested | 1 |
| 43 | household-randomized | 2 |
| 44 | double-blind-randomized | 3 |
| 45 | pilot-randomized | 1 |
| 46 | pre-post-randomized | 1 |
| 47 | enid | 2 |
| 48 | diamondoid | 1 |
| 49 | rated-blind | 1 |
| 50 | un-blind | 1 |
| 51 | within-wound | 1 |
| 52 | oulu-bpd | 1 |
| 53 | multiple-probe | 1 |
| 54 | vaccine-probe | 2 |
| 55 | single-orifice | 2 |
| 56 | fixed-sequence | 12 |
| 57 | pulse-sequence | 2 |
| 58 | four-sequence | 2 |
| 59 | mock-package | 1 |
| 60 | measure.the | 2 |
| 61 | diabetes.the | 1 |
| 62 | protocols.the | 1 |
| 63 | isthe | 1 |
| 64 | scaffold-like | 2 |
| 65 | zelen-like | 1 |
| 66 | cross-over-like | 2 |
| 67 | stiffness-adjustable | 1 |
| 68 | doxycycline-metronidazole | 1 |
| 69 | three-outcome | 5 |
| 70 | dimethyldihydropyrene | 1 |
| 71 | multiple-baseline | 16 |
| 72 | n-g-dimethylarginine | 1 |
| 73 | stroke.one | 1 |
| 74 | barite-type | 1 |
| 75 | intervention/usual-care | 1 |
| 76 | latin-square | 17 |
| 77 | outcomes-measure | 1 |
| 78 | analysis.acupuncture | 1 |
| 79 | 4-phase | 9 |
| 80 | placebo-phase | 4 |
| 81 | ascending-dose | 28 |
| 82 | rising-dose | 6 |
| 83 | fixeddose | 2 |
| 84 | simulated-use | 3 |
| 85 | remote-confederate | 1 |
| 86 | case-vignette | 3 |
| 87 | control-comparative | 1 |
| 88 | responsive-adaptive | 1 |
| 89 | rcts.twelve | 1 |
| 90 | paired-eye | 17 |
| 91 | one-eye | 2 |
| 92 | two-eye | 3 |
| 93 | dog-leg | 6 |
| 94 | dose-finding | 205 |
| 95 | regimen-finding | 2 |
| 96 | dose-ranging | 236 |
| 97 | placebo-challenging | 1 |
| 98 | forced-switching | 1 |
| 99 | dose-escalating | 62 |
| 100 | battenburg | 1 |
| 101 | danish-dutch | 1 |
| 102 | half-mouth | 4 |
| 103 | split-mouth | 327 |
| 104 | splitmouth | 2 |
| 105 | topiq-ii | 1 |
| 106 | scami | 3 |
| 107 | costami | 2 |
| 108 | switchback | 11 |
| 109 | two-attack | 2 |
| 110 | balanced-block | 1 |
| 111 | randomized-block | 1 |
| 112 | variable-block | 1 |
| 113 | complete-block | 3 |
| 114 | event-related/block | 1 |
| 115 | 72-wk | 1 |
| 116 | psychophenomenological | 1 |
| 117 | controlled-clinical | 3 |
| 118 | factorial | 1,401 |
| 119 | 2-factorial | 9 |
| 120 | sequential-factorial | 1 |
| 121 | full-factorial | 20 |
| 122 | prefactorial-postfactorial | 1 |
| 123 | methods/trial | 1 |
| 124 | cross-sequential | 1 |
| 125 | cohort-sequential | 1 |
| 126 | d-optimal | 14 |
| 127 | penta-gonal | 1 |
| 128 | co-relational | 1 |
| 129 | longitudinal-observational | 1 |
| 130 | single-reversal | 2 |
| 131 | quasiexperimental | 32 |
| 132 | change-to-open-label | 1 |
| 133 | one-nostril | 1 |
| 134 | delayed-control | 1 |
| 135 | randomized-control | 11 |
| 136 | equivalent-control | 1 |
| 137 | pre-post-control | 1 |
| 138 | case-pseudocontrol | 1 |
| 139 | multiarm | 10 |
| 140 | h.mean | 1 |
| 141 | plackett-burman | 19 |
| 142 | within-between | 3 |
| 143 | box-behnken | 31 |
| 144 | investigator-open | 1 |
| 145 | food-challenge-proven | 1 |
| 146 | factorial-design | 11 |
| 147 | crossover-design | 11 |
| 148 | test-vein | 1 |
| 149 | multioccasion | 1 |
| 150 | dose-validation | 1 |
| 151 | dose-escalation | 246 |
| 152 | escalation/descalation | 1 |
| 153 | three-formulation | 1 |
| 154 | dose-confirmation | 2 |
| 155 | crossover-combination | 1 |
| 156 | forced-titration | 16 |
| 157 | effectiveness/implementation | 1 |
| 158 | 3-station | 1 |
| 159 | fluoxetine-discontinuation | 1 |
| 160 | 4-condition | 1 |
| 161 | pre-and-post-intervention | 1 |
| 162 | dietary-intervention | 7 |
| 163 | paraffin-adsorption | 1 |
| 164 | treatment-comparison | 1 |
| 165 | box-wilson | 1 |
| 166 | crxo | 12 |
| 167 | pre-test/posttest/follow-up | 1 |
| 168 | pretest/posttest/follow-up | 2 |
| 169 | 4-group | 9 |
| 170 | sequential-group | 4 |
| 171 | two-parallel-group | 4 |
| 172 | four-group | 19 |
| 173 | parallelgroup | 2 |
| 174 | split-scar | 6 |
| 175 | pens/feeder | 1 |
| 176 | randomized-to-order | 1 |
| 177 | play-the-winner | 14 |
| 178 | web-user | 1 |
| 179 | exophthalmometer | 4 |
| 180 | randomized-cluster | 1 |
| 181 | change-over | 5 |
| 182 | cross-over | 2,794 |
| 183 | 2,2,2-cross-over | 1 |
| 184 | crossover | 7,573 |
| 185 | randomised-crossover | 1 |
| 186 | randomized-crossover | 6 |
| 187 | two-period-crossover | 1 |
| 188 | double-crossover | 8 |
| 189 | triple-crossover | 10 |
| 190 | multiple-crossover | 4 |
| 191 | self-crossover | 3 |
| 192 | semi-crossover | 2 |
| 193 | two-crossover | 2 |
| 194 | cluster-crossover | 1 |
| 195 | semicrossover | 1 |
| 196 | 9-factor | 1 |
| 197 | trias | 3 |
| 198 | healthservices | 1 |
| 199 | one-group-repeated-measures | 1 |
| 200 | between-measures | 1 |
| 201 | intervention.this | 2 |
| 202 | immunotherapy.this | 1 |
| 203 | between-persons | 1 |
| 204 | parallel-groups | 40 |
| 205 | three-parallel-groups | 1 |
| 206 | independent-groups | 1 |
| 207 | nonequivalent-groups | 1 |
| 208 | eurofors | 1 |
| 209 | single-subjects | 1 |
| 210 | between-subjects | 162 |
| 211 | within/between-subjects | 2 |
| 212 | within-subjects | 135 |
| 213 | between/within-subjects | 1 |
| 214 | between-participants | 16 |
| 215 | within-participants | 7 |
| 216 | penthifra-plus | 2 |
| 217 | rt/ct | 1 |
| 218 | titration-to-effect | 2 |
| 219 | buma-oct | 2 |
| 220 | factorial-rct | 1 |
| 221 | 6-visit | 3 |
| 222 | single-participant | 2 |
| 223 | pbr-relevant | 1 |
| 224 | d-efficient | 9 |
| 225 | 1,160-patient | 1 |
| 226 | 234-patient | 1 |
| 227 | treatment-assignment | 3 |
| 228 | prevention+treatment | 1 |
| 229 | pre-post-treatment | 1 |
| 230 | split-plot | 22 |
| 231 | test-of-concept | 2 |
| 232 | pascart | 1 |
| 233 | 2-cohort | 4 |
| 234 | prospective-cohort | 2 |
| 235 | test/re-test | 1 |
| 236 | pre-post-test | 3 |
| 237 | pre-test-post-test | 13 |
| 238 | pretest-post-test | 12 |
| 239 | pre-/post-test | 11 |
| 240 | pre/post-test | 1 |
| 241 | pre-test–post-test | 1 |
| 242 | pretest-training-posttest | 1 |
| 243 | pre-test-posttest | 1 |
| 244 | pretest-test-posttest | 1 |
| 245 | pretest-posttest | 136 |
| 246 | pre-/posttest | 5 |
| 247 | pretest/posttest | 15 |
| 248 | pretestposttest | 1 |
| 249 | uht-htst | 1 |
| 250 | reactt | 1 |
| 251 | δ-minimax | 5 |
| 252 | 108-day | 1 |
| 253 | paired-study | 1 |
| 254 | parallel-study | 1 |
| 255 | intervention-study | 1 |
| 256 | years.study | 1 |
| 257 | delivery.study | 1 |
| 258 | method/study | 1 |
| 259 | hearthealthy | 1 |
| 260 | one-group-only | 1 |
| 261 | posttest-only | 18 |
| 262 | conversion-to-monotherapy | 4 |
| 263 | supersecondary | 1 |
| 264 | no-inferiority | 1 |
| 265 | 'superiority | 1 |
| 266 | regression-discontinuity | 2 |